-
-
Call more information
660-596-2224 -
The FDA has granted accelerated approval for idarucizumab (Praxbind) to reverse the anticoagulant effects of dabigatran (Pradaxa) in emergency situations. Idarucizumab, an injectable monoclonal antibody fragment, binds to dabigatran and thereby neutralizes its effect. Approval was based on three trials in which some 280 healthy adults who did not require anticoagulant therapy were given dabigatran […]
Read MoreAuthors: Andrews PJD et al., N Engl J Med 2015 Oct 7; A multicenter randomized trial was stopped early because hypothermia worsened outcomes when used as second-line therapy for elevated intracranial pressure. Induced hypothermia has become popular for treating cerebral edema from traumatic brain injury (TBI), but we do not know the effect on long-term […]
Read MoreDear Q&A, We write to describe an instance of anesthesia machine ventilator failure during provision of anesthesia. The case in point was an emergency vascular operation for a pulseless lower extremity. In preparation for the case, the anesthesia machine checkout was performed on the Dräger GS Premium. All tests confirmed that the anesthesia machine was […]
Read MoreDear Q&A, We were using oxygen and air with sevoflurane for a case in the cystoscopy suite. During the maintenance phase of the case, we found what we assumed to be water inside the air flowmeter, with its float rising and dropping rapidly and the liquid spilling into the next flowmeter (nitrous oxide). We promptly […]
Read MoreBy Lorri A. Lee, MD, and Tricia A. Meyer, PharmD, MS, FASHP An estimated one million people in the United States have been diagnosed with Parkinson’s Disease (PD) making it one of the most common neurological disorders in patients. This number is estimated to double in the next 30 years as PD is associated with […]
Read More